News
Scholar Rock named current chairman David Hallal as its new CEO, succeeding Jay Backstrom. The Bloc, a 2024 MM+M Agency 100 ...
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for ...
The incoming CEO is David Hallal, the chairman of the company's board. As CEO, he succeeds Jay Backstrom, who is transitioning into a role as strategic advisor. Hallal served in several managerial ...
Hallal has succeeded Jay Backstrom, who will serve as a strategic advisor, working closely with Scholar Rock's executive team and Board. In addition, the company has appointed Vikas Sinha ...
announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just ...
Akshay Vaishnaw, M.D., Ph.D., has been appointed to the newly created role of President of R&D. He was formerly the President ...
Despite the increasingly competitive environment, Celgene’s chief medical officer Jay Backstrom said “we believe that ozanimod has the potential to be an important option early in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results